Skip to main content
. 2012 May 31;107(1):75–83. doi: 10.1038/bjc.2012.212

Figure 5.

Figure 5

Methylation of the NT5E CpG island in primary breast carcinomas influences clinical outcome. (A) Representative methylation-specific PCR analysis of the NT5E CpG island in series III breast carcinomas. The figure shows unmethylated (U) and methylated (M) reactions for each individual case DNA (numbered 1–16). Also shown are control U and M DNA samples modified in parallel with the cell line DNA samples. (B) Metastatic relapse is more frequent in patients whose primary breast carcinoma lacks methylation in the NT5E CpG island. The figure shows number of patients with metastatic relapse as a function of the methylation status of the NT5E CpG island (M, U). All: N=157; TNBC: N=26; ER−: N=38; ER+: N=119. (C) Kaplan–Meir analysis of disease-free survival (DFS) in primary breast carcinomas according to methylation status of NT5E CpG island. Methylation in the NT5E CpG island was analysed by MSP and statistical analysis done as described in Materials and Methods. The figure shows DFS in primary cancers either M or U. (D) Kaplan–Meir analysis of OS in primary breast carcinomas according to methylation status of NT5E CpG island. Methylation in the NT5E CpG island was analysed by methylation-specific PCR and statistical analysis done as described in Materials and Methods. The figure shows OS in primary cancers either M or U. Abbreviations: ALL=entire patient population; ER−=oestrogen receptor negative; ER+=oestrogen receptor positive; MSP=methylation-specific PCR; TNBC=triple-negative breast cancer.